Skip to content
Latest Updates
Sri Krishna Jubilee Law College to organise 2nd L.P. Shahi Memorial National Moot Court Competition on February 6—7, 2027 Six Indian startups selected for Hub71’s immersion programme at UAE Embassy’s UAE-India Start-Up series 2.0 finale 5th ALCICON—2026: Asian Law College to host international conference on emerging trends in technology, law and sustainability in collaboration with Kutafin Moscow State Law University Myanmar committed genocide against Rohingya group in Northern Rakhine State during 2017 ‘Clearance Operations’: ICJ Delhi High Court: Aadhaar Card Not Conclusive Proof of Date of Birth; ESIC Records Prevail in Superannuation Dispute Shardul Amarchand Mangaldas & Co. advises Anupam Rasayan India Ltd. on acquisition of a controlling stake in Bliss GVS Pharma Ltd.

Pfizer to combine off-patent drug business with Mylan

Content reader

Listen to this article

Ready to read this article aloud.
Pfizer to combine off-patent drug business with Mylan

As reported by CNBC, Pfizer is set to combine its off-patent drug business with Mylan– a generic drugmaker.

Pfizer shareholders would own 57% of the combined new company and Mylan shareholders would own 43%.

“Combined company, which will sell Mylan’s EpiPen and Pfizer’s Viagra, will be domiciled in the U.S. The deal will be structured in what’s known as a reverse Morris trust, with Pfizer’s Upjohn business divested and then combined with Mylan.”

It has been further reported that, New Pfizer venture will focus on drugs where exclusivity has expired. It will combine generic medicines, often made by different companies than the original drug, with off-patent drugs, which Pfizer used to sell as key brands before their patent protection ended.


[Source: CNBC]

[Image Credits: Financial Express]

WhatsApp LinkedIn

0 replies

Leave a Reply

Your email address will not be published. Required fields are marked *.

This site uses Akismet to reduce spam. Learn how your comment data is processed.